NewLimit, a South San Francisco company developing medicines that reverse cellular ageing, raised a $435m Series C on 2 June 2026. Founders Fund led the round.
Chief executive Jacob Kimmel put the valuation at about $3.1bn, according to STAT. Thrive Capital, Greenoaks and Quiet Capital joined as new investors, while Kleiner Perkins, Nat Friedman, Daniel Gross and Eli Lilly Ventures returned, according to BioSpace.
The money will fund the company's first clinical asset and its move into human testing, which BioSpace reported is planned for next year.
What NewLimit does
NewLimit works on epigenetic reprogramming: using transcription factor payloads to restore youthful function in old cells. Its website describes a discovery engine that pairs an AI system designing payloads with high-throughput testing of thousands of designs at once. Initial programmes target the liver, immune system and blood vessels.
The company says a prototype medicine reversed cell age in old human liver cells. Its first clinical candidate is a liver medicine intended to help the organ heal faster after injury, prevent damage from dietary challenges and speed recovery related to alcohol consumption, BioSpace reported.
BioSpace also reported that the company had originally expected a decade-plus path to the clinic but now expects to move faster.
Who founded it
NewLimit was founded in 2021 by Brian Armstrong, chief executive and co-founder of Coinbase, Blake Byers, a former GV partner and bioengineer, and Jacob Kimmel, a stem cell biologist who is now chief executive.
The company's own account is that ageing is plastic at the cellular level. A NewLimit blog post cited by BioSpace says reversing cellular age has the potential to treat diseases of ageing and preserve health in nearly everyone. That is the company's own claim.
The funding so far
STAT reported that NewLimit raised $130m in a Series B in May 2025 and a further $45m in October of that year, making this the third raise in about a year. BioSpace said the company raised $130m the prior year, which is consistent.
The Series C is more than three times the Series B. STAT's report on the round was partly paywalled, so details beyond the lead investor, the valuation and a few named participants were taken from BioSpace.
A well-funded field
Longevity companies have attracted large rounds from technology investors, and NewLimit's round is one of the larger ones in the field. The presence of Eli Lilly Ventures gives it a pharmaceutical-industry backer alongside the venture funds.
The company did not disclose its headcount in the sources opened for this article. Whether the liver programme moves into patients as planned will be the first clinical test of the approach.
STAT reported the valuation as being given by Kimmel himself, and it is not an independently audited figure. The company's own website says only that it is inventing medicines to add healthy years to people's lives, without giving financial details.
Company website: newlimit.com